PROTEOSTASIS THERAPEUTICS, INC. | Business Finance | Business Contracts

Form of Amendment No. 4 to Securities Purchase Agreement, dated May 1, 2023 (Filed With SEC on June 2, 2023)

Form of Pre-Funded Warrant (Filed With SEC on April 21, 2023)

Form of Common Warrant (Filed With SEC on April 21, 2023)

Form of Wainwright Warrant (Filed With SEC on April 21, 2023)

Form of Securities Purchase Agreement, dated as of April 20, 2023 (Filed With SEC on April 21, 2023)

Form of Amendment No. 2 to the Securities Purchase Agreement dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Warrant, dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Amendment No. 2 to the Registration Rights Agreement, dated December 5, 2022 (Filed With SEC on December 5, 2022)

Form of Securities Purchase Agreement Amendment, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Form of Warrant, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Form of Registration Rights Agreement Amendment, dated October 24, 2022 (Filed With SEC on October 24, 2022)

Kineta, Inc. Amended and Restated 2008 Stock Plan (the Kineta 2008 Plan) and associated forms (Filed With SEC on August 29, 2022)

Asset Purchase Agreement, dated June 5, 2022, by and among Yumanity and Janssen (Filed With SEC on June 6, 2022)

Form of Securities Purchase Agreement, dated June 5, 2022, by each of the parties named therein (Filed With SEC on June 6, 2022)

Form of Registration Rights Agreement, dated June 5, 2022, by each of the parties named therein (Filed With SEC on June 6, 2022)

Sixth Amendment and Consent to Loan and Security Agreement dated as of April 13, 2021, by and among Yumanity, Inc., the lenders party thereto and Hercules Capital, Inc (Filed With SEC on August 12, 2021)

Fifth Amendment and Consent to Loan and Security Agreement dated as of March 29, 2021, by and among Yumanity, Inc., the lenders party thereto and Hercules Capital, Inc (Filed With SEC on May 13, 2021)

Amended and Restated Warrant Agreement to Purchase Common Stock of the Company issued to Hercules Capital, Inc., dated December 22, 2020 (Filed With SEC on March 31, 2021)

Unconditional Secured Guaranty and Pledge Agreement, dated December 22, 2020 by and between the Company (formerly known as Proteostasis Therapeutics, Inc.) and Hercules Capital,... (Filed With SEC on December 30, 2020)

Fourth Amendment and Consent to Loan and Security Agreement dated as of December 22, 2020, by and among Yumanity, Inc. (formerly Yumanity Therapeutics, Inc.), the lenders party... (Filed With SEC on December 30, 2020)

Registration Rights Agreement, dated as of December 22, 2020 by among the Company (formerly known as Proteostasis Therapeutics, Inc.) and certain purchasers listed therein (Filed With SEC on December 30, 2020)

Yumanity Therapeutics, Inc. Amended and Restated 2018 Stock Option and Grant Plan and forms of award agreements thereunder (Filed With SEC on December 30, 2020)

Subscription Agreement, dated as of December 14, 2020 by and among Proteostasis Therapeutics, Inc. and the Purchasers named therein (Filed With SEC on December 15, 2020)

Form of Registration Rights Agreement (Filed With SEC on December 15, 2020)

Loan and Security Agreement, by and among Yumanity Therapeutics, Inc. and Hercules Capital, Inc., dated as December 20, 2019 (Filed With SEC on September 23, 2020)

Warrant Agreement to Purchase Preferred Units of Yumanity Holdings, LLC issued to Hercules Capital, Inc., dated December 20, 2019 (Filed With SEC on September 23, 2020)

U.S. Small Business Administration Paycheck Protection Program Note with Silicon Valley Bank, dated as of April 24, 2020 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Alexandria Equities, LLC (as predecessor to Alexandria Venture Investments, LLC) on October 9, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Redmile Capital Offshore II Master Fund, Ltd. on August 14, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to Redmile Biotechnologies Investments I AF, LP (as predecessor to Redmile Biopharma Investments I, L.P.) on August 14, 2015 (Filed With SEC on September 23, 2020)

Common Unit Warrant issued to N. Anthony Coles on August 14, 2015 (Filed With SEC on September 23, 2020)

Warrant to Purchase Limited Liability Company Interests issued to Silicon Valley Bank on June 14, 2018 (Filed With SEC on September 23, 2020)

Warrant to Purchase Limited Liability Company Interests issued to Oxford Finance LLC dated June 14, 2018 (Filed With SEC on September 23, 2020)

Assignment and Release Agreement between the Company and Cystic Fibrosis Foundation, dated December 19, 2018 (Filed With SEC on March 8, 2019)

Underwriting Agreement, dated October 23, 2018 (Filed With SEC on October 24, 2018)

Underwriting Agreement, dated December 13, 2017 (Filed With SEC on December 15, 2017)

Proteostasis Therapeutics, Inc. [] Shares Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on August 31, 2016)

Proteostasis Therapeutics, Inc. [] Shares Common Stock (par value $0.001 per share) Underwriting Agreement (Filed With SEC on February 10, 2016)

PROTEOSTASIS THERAPEUTICS, INC. 2016 EMPLOYEESTOCK PURCHASE PLAN (Filed With SEC on February 1, 2016)

PROTEOSTASIS THERAPEUTICS, INC. (127) | Business Finance (39)